While the exact mechanism behind reduced CB1 receptor levels in psychosis is not fully understood, research indicates that synthetic CB1R agonists or AEA analogues can trigger CB1R internalization through endocytosis, leading to decreased receptor expression on the cell surface. This evidence concerns the gene CNR1 and psychotic disorder.